Multiple endogenous coagulation factors and plasma proteins

Multiple endogenous coagulation factors and plasma proteins refers to a collective group of proteins, primarily serine proteases, that circulate in the blood and are essential for the maintenance of hemostasis (StatPearls: Physiology, Coagulation Cascade). This group includes key components of the coagulation cascade such as Factor II (prothrombin), Factor VII, Factor IX, Factor X, and Factor XI, as well as regulatory proteins like plasmin and kallikrein (FDA Label: Trasylol). These proteins function through a series of proteolytic activations that ultimately lead to the formation of a stable fibrin clot or the dissolution of such clots through fibrinolysis (UniProt: Coagulation Factor X). In clinical practice, these factors are targeted by a variety of pharmacological agents to either promote clotting in cases of severe hemorrhage or prevent pathological thrombosis (PubChem: Aprotinin). For example, aprotinin acts as a broad-spectrum inhibitor of these proteases to reduce blood loss during complex surgeries, while anticoagulants like heparin indirectly modulate their activity via antithrombin (NIH: Heparin). Because this target group encompasses a wide array of proteins with opposing functions, drugs interacting with this group must be carefully managed to avoid the risks of either excessive bleeding or unwanted systemic thromboembolism (PubMed: Safety of Aprotinin in Cardiac Surgery).

Other names

Coagulation factorsPlasma serine proteasesHemostatic proteinsClotting factors

Mechanisms include the direct inhibition of serine protease activity, indirect inhibition via activation of antithrombin, inhibition of vitamin K-dependent synthesis of factors, and the direct replacement of deficient factors.